Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

A high-throughput chemotaxis assay for pharmacological characterization of chemokine receptors: Utilization of U937 monocytic cells.

Ott TR, Pahuja A, Lio FM, Mistry MS, Gross M, Hudson SC, Wade WS, Simpson PB, Struthers RS, Alleva DG.

J Pharmacol Toxicol Methods. 2005 Mar-Apr;51(2):105-14. Epub 2004 Nov 5.

PMID:
15767203
2.

Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry.

Princen K, Hatse S, Vermeire K, De Clercq E, Schols D.

Cytometry A. 2003 Jan;51(1):35-45.

3.

CK beta-11/macrophage inflammatory protein-3 beta/EBI1-ligand chemokine is an efficacious chemoattractant for T and B cells.

Kim CH, Pelus LM, White JR, Applebaum E, Johanson K, Broxmeyer HE.

J Immunol. 1998 Mar 1;160(5):2418-24.

4.

Synergy between proinflammatory ligands of G protein-coupled receptors in neutrophil activation and migration.

Gouwy M, Struyf S, Catusse J, Proost P, Van Damme J.

J Leukoc Biol. 2004 Jul;76(1):185-94. Epub 2004 Apr 9.

PMID:
15075362
5.
6.

Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.

Hatse S, Princen K, Liekens S, Vermeire K, De Clercq E, Schols D.

Cytometry A. 2004 Oct;61(2):178-88.

7.

Ephrin stimulation modulates T cell chemotaxis.

Sharfe N, Freywald A, Toro A, Dadi H, Roifman C.

Eur J Immunol. 2002 Dec;32(12):3745-55.

8.

Cloning and functional characterization of the rabbit C-C chemokine receptor 2.

Lu D, Yuan XJ, Evans RJ Jr, Pappas AT, Wang H, Su EW, Hamdouchi C, Venkataraman C.

BMC Immunol. 2005 Jul 7;6:15.

9.

Identification of CC chemokine receptor 7 residues important for receptor activation.

Ott TR, Pahuja A, Nickolls SA, Alleva DG, Struthers RS.

J Biol Chem. 2004 Oct 8;279(41):42383-92. Epub 2004 Jul 28.

10.

Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor.

Struyf S, Proost P, Sozzani S, Mantovani A, Wuyts A, De Clercq E, Schols D, Van Damme J.

J Immunol. 1998 Sep 15;161(6):2672-5.

12.
13.

I-TAC/CXCL11 is a natural antagonist for CCR5.

Petkovic V, Moghini C, Paoletti S, Uguccioni M, Gerber B.

J Leukoc Biol. 2004 Sep;76(3):701-8. Epub 2004 Jun 3.

PMID:
15178708
14.

A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes.

Hieshima K, Imai T, Baba M, Shoudai K, Ishizuka K, Nakagawa T, Tsuruta J, Takeya M, Sakaki Y, Takatsuki K, Miura R, Opdenakker G, Van Damme J, Yoshie O, Nomiyama H.

J Immunol. 1997 Aug 1;159(3):1140-9.

PMID:
9233607
15.

Serum amyloid A chemoattracts immature dendritic cells and indirectly provokes monocyte chemotaxis by induction of cooperating CC and CXC chemokines.

Gouwy M, De Buck M, Pörtner N, Opdenakker G, Proost P, Struyf S, Van Damme J.

Eur J Immunol. 2015 Jan;45(1):101-12. doi: 10.1002/eji.201444818. Epub 2014 Dec 1.

16.

Synthetic chemokines directly labeled with a fluorescent dye as tools for studying chemokine and chemokine receptor interactions.

Strong AE, Thierry AC, Cousin P, Moulon C, Demotz S.

Eur Cytokine Netw. 2006 Mar;17(1):49-59.

17.

STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13.

Andrew DP, Chang MS, McNinch J, Wathen ST, Rihanek M, Tseng J, Spellberg JP, Elias CG 3rd.

J Immunol. 1998 Nov 1;161(9):5027-38.

18.

Mature monocyte-derived dendritic cells respond more strongly to CCL19 than to CXCL12: consequences for directional migration.

Humrich JY, Humrich JH, Averbeck M, Thumann P, Termeer C, Kämpgen E, Schuler G, Jenne L.

Immunology. 2006 Feb;117(2):238-47.

19.
20.

The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis.

Trentin L, Agostini C, Facco M, Piazza F, Perin A, Siviero M, Gurrieri C, Galvan S, Adami F, Zambello R, Semenzato G.

J Clin Invest. 1999 Jul;104(1):115-21.

Supplemental Content

Support Center